BMRN Stock Analysis: Buy, Sell, or Hold?
BMRN - BioMarin Pharmaceuticals Inc
$56.50
0.60 (1.07%)
▲
5d:
+1.53%
30d:
+4.44%
90d:
+3.14%
BUY
MODERATE Confidence
Analysis Updated: Jun 23, 2026 12:00 AM ET
Earnings: Aug 03, 2026
Smart Money Accumulation
None View Scanner →
Strength: 4.7/10
Get Alerted When BMRN Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
💡 BUY OPPORTUNITY: BMRN shows positive signals but monitor for confirmation. Market pricing in 2.5% decline. Moderate conviction.
💡 BUY OPPORTUNITY: BMRN shows positive signals but monitor for confirmation. Market pricing in 2.5% decline. Moderate conviction.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$118.32
Based on 14.5% avg growth
INTRINSIC VALUE TODAY
$73.47
23.1% Margin of Safety
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 9.4x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: BMRN is currently trading at $56.50, which is considered slightly high relative to its 30-day fair value range of $52.24 to $56.70. The stock's valuation (Forward PE: 8.7) is in line with its historical norms (9.4). Remarkably, the market is currently pricing in an annual earnings decline of 2.5% over the next few years. This aligns with recent fundamental challenges.
Technical Outlook: Technically, BMRN is in a downtrend. Immediate support is located at $54.26, while resistance sits at $58.26.
Market Sentiment: The stock shows a mixed technical setup (55/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $87.85 (+55.5%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, BMRN is in a downtrend. Immediate support is located at $54.26, while resistance sits at $58.26.
Market Sentiment: The stock shows a mixed technical setup (55/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $87.85 (+55.5%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
SLIGHTLY HIGH
Historical Trading Range
$52.24 -
$56.70
Company Quality Score
65/100
(BUY)
Volume Confirmation
HIGH
Confidence Score
65.2%
All Signals
- NEUTRAL: Mixed technical signals (55/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 55.5% below Wall St target ($87.85)
Trading Range Analysis
30-Day Trading Range
$52.24 -
$56.70
Current vs Trading Range
SLIGHTLY HIGH
Support & Resistance Levels
Support Level
$54.26
Resistance Level
$58.26
Current Trend
Downtrend
Technical data as of
Jun 23, 2026
Fundamental Context
Forward P/E (Next Year Est.)
8.74
Wall Street Target
$87.85
(+55.5%)
Revenue Growth (YoY)
2.8%
Earnings Growth (YoY)
-43.1%
Profit Margin
8.3%
Valuation Discount vs History
-2.5% cheaper
PE vs Historical
8.7 vs 9.4
FAIR
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
-2.5%
(market-implied from PE analysis)
1-Year Target
$55.09
(-3%)
2-Year Target
$53.71
(-5%)
3-Year Target
$52.37
(-7%)
3-Yr Target (if PE normalizes)
(PE: 9→9)
$56.31
(0%)
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 21.8, Growth: 30.9%)
$315.91
(+459%)
Base:
(SPY PE: 8.7, Growth: 30.9%)
$126.79
(+124%)
Bear:
(PE: 7.4, Growth: 30.9%)
$107.77
(+91%)
📈
Valuation based on Current Earnings
RECOVERY PLAY: Stock looks expensive now (40x PE), but valuation improves significantly next year (9x PE) as earnings recover.
Trailing PE: 40.22 | Current EPS (TTM): $1.39
Bull Case
$122.98
(+118%)
Analyst growth 100.0%, PE expands to 44.2
Base Case
$111.80
(+98%)
Market implied 100.0%, PE stable at 40.2
Bear Case
$38.01
(-33%)
Severe decline -20.0%, PE contracts to 34.2
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
💡
Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 8.7 to 9.4
Stabilization Target:
$60.76
(+7.5%)
PE Expansion Potential:
+7.5%
Share & Embed Analysis
Last updated: June 23, 2026 6:51 PM ET
Data refreshes hourly during market hours. Next update: 7:51 PM
Data refreshes hourly during market hours. Next update: 7:51 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is BMRN showing a specific setup today?
Insider Activity (6 Months)
0
Buys
2
Sells
Net
INSIDERS SELLING
Recent Transactions
Charles Greg Guyer
SELL
16486 shares
2026-03-11
Gregory R Friberg
SELL
6326 shares
2026-02-26
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NTLA
Intellia Therapeutics Inc |
STRONG BUY
29 analysts |
$27 | 56 HOLD |
|
ONC
BeiGene, Ltd. |
STRONG BUY
24 analysts |
$412 | 57 HOLD |
|
ARGX
argenx NV ADR |
STRONG BUY
22 analysts |
$1022 | 67 BUY |
|
INSM
Insmed Inc |
STRONG BUY
21 analysts |
$197 | 61 BUY |
|
ACLX
Arcellx Inc |
STRONG BUY
18 analysts |
$113 | 57 HOLD |
Advanced BMRN Option Strategies
Professional options setups generated by AI based on today's BMRN price and gamma walls.
